Skin melanoma represents one of the most common and lethal solid tumor. It usually develops on the skin but it can occur in any tissues with melanine-containing-cells (extracutaneous malignant melanoma). Only 4-5% of malignant melanomas originate in extracutaneous tissues, and they have an extremely lethal behavior (1). These non-skin malignant melanomas are rare but extremely aggressive. Primary melanoma of the genitourinary tract accounts for less than 0.2% of all melanomas. To date only 28 cases of primary bladder melanoma (PMM) are described. We report a rare case of PMM of the bladder in a 72 years old man treated with radical cystectomy and immunotherapy with Nivolumab.
troscopy,colonscopy and a ophthalmologic exam ruled out the suspicious of a secondary lesion from a primitive malignant melanoma elsewhere. Patient' s case was discussed by the institutional multidisciplinary uro-oncologic disease management team that stated a multimodal treatment. A radical cystectomy with a simple urinary diversion (UCS) and immunotherapy protocol were planned. Patient underwent surgery and the final histological exam reported a pT4 N0 Mx R0 melanoma of the bladder ( Figure 1 ). Immunoistochemical exam was positive for S-100, and SOX-10 and slightly positive for HMB45 while was negative for Cytocheratines CAM5.2, AE/1/AE3, 7, 20; Actine, CD34, Desmin,DOG-1, EMA, GATA-3, Myogenine, Chromoreanine, PSA and P63 (Figure 1 ). Two months after surgery patient underwent contrast enhancement computed tomography (CeCT) without showing progression of the chest nodes. Three months DOI: 10.4081/aiua.2018.3.224
CASE REPORT
A 72 year-old caucasian man presented to the Emergency Room of our Hospital with gross asymptomatic haematuria. A cystoscopy showed a solid mass with red and brown spots in the surface, consequently the diagnosis of solid bladder tumor was posed. After obtaining informed consent, we performed a trans urethral resection of the bladder tumor (TURBt) without a radical debulking of the whole mass due to the aspect of extensive muscle invasion. The histological exam confirmed the diagnosis of PMM of the bladder. Patient denied an history of nevi-excision or other surgery. A multiparametric Magnetic Resonance (mpMR) scan confirmed a solid tumor of 7x6 cm. The lesion extended through all the bladder wall with suspicious iliac nodal metastasis. A fluorodeoxyglucose positron emission tomography computed tomography (FDG PET-CT) scan showed hypermetabolic capitation of the right ilar lymph-nodes and of the mesenteric tissue. A single capitation in para-vertebral region of the low portion of left lung was not clearly identified as metastasis. Dermatological exam, gas- after surgery patient underwent immunotherapy with Nivolumab as for skin melanoma. A 14 day course of intravenous injections of 3 mg/kg of Nivolumab in 100 ml of saline solution was completed. A new FDG PET-CT scan six months after surgery showed a complete response of the nodal and mesenteric lesions while reported a decrease in size of the pulmonary lesion (17 mm vs 21 mm). Thirteen months after surgery, a new FDG PET-CT showed a 4 mm small right inguinal nodal recurrence and a steady situation of the pulmonary lesion. Fifteen months after surgery patient is alive with Karnofsky score of 90 and ECOG 1-2.
DISCUSSION
Primary melanoma of the urinary bladder is an extremely rare neoplasm and to date only 28 cases including this case are reported to medical literature ( Table 1) . The diagnosis of primary melanoma of the bladder is not always easy. Ainsworth et al. (2) and Siroy and MacLennan (3) established some diagnostic criteria for primary bladder tumours:
(1) absence of any previous skin lesion, or (2) cutaneous malignant melanoma, or (3) primary visceral malignant melanoma, (4) recurrence pattern showing consistency with the primary tumour diagnosis, (5) atypical melanocytes at the tumour margin on microscopic examination. Primary melanoma of the urinary bladder usually affects people over fifty and there is a slight prevalence in male sex (60%). Our literature review presents few cases over a wide range of time with extremely different treatments and behavior. In addition, the follow up is extremely heterogeneous and only 12/28 patients (42%) were alive at time of the report with different follow-up (3-144 months; median 20.7 months). First choice treatment is surgery. The treatment can be conservative as trans urethral resection of the bladder tumor (TURBt) associated or not with endovesical Immunotherapy with Bacillus of Calmette Guerin (BCG); partial cystectomy can be considered as alternative conservative treatment. Radical Cystectomy can be carried out based on the staging of tumor and in patients with better performance status. Chemotherapy can be a possibility as unique therapy for patients who are poor surgical candidates and options include platinum-based chemotherapy as cisplatin/carboplatin plus paclitaxel. Immunotherapy can be considered optional. Interferon and interleukin (IL)-2 are used for metastatic melanoma but the high tossicity and the low response rate reported in literature considerably limited the use. (4, 5) . Other treatment as radiation therapy might be only considered for palliative treatment in bladder melanoma. Based on our review TURBt or other conservative treatments were carried out in 14 patients (50%) with a survival rate of 28.5% (4/14) in an average follow up of 14 months. One patient was treated with conservative treatment (TURBt) along with a combination of Interferon plus Dacarbazine and died after 18 months. In one case treated with TURBt and Ipilimumab survival was not reported. Three cases did not receive any treatment and the reported follow up showed a death in 2 months and 8 months and a survival at 6 months. One case was treated with chemotherapy alone and died after 18 months. Radical cystectomy was carried out in 10 patients with median age of 59 y/o; survival rate was 60% (6/10) at a median follow up of 15.5 months. Among patients treated with cystectomy, one received also radiotherapy and died 16 months after primary treatment. One patient received a multimodal treatment combined of cystectomy, radiotherapy and immunotherapy with interferon alpha and died 24 months after. In our case, Nivolumab was started as first line treatment after surgery based upon the BRAF, NRAS and c-KIT wild type molecular pattern. At time of this literature review is the only one reported with clinical and metabolic remission 15 months after primary treatment without relevant toxicities.
